52-Week Efficacy and Safety Results from SPIRIT-P1: A Phase 3 Study of Ixekizumab in Patients with Active Psoriatic Arthritis

被引：0

作者：

Mease, Philip ^{[1
,2
]}

Okada, Masan ^{[3
]}

Kishimoto, Mitsumasa ^{[4
]}

Shuler, Catherine ^{[5
]}

Carlier, Hilde ^{[5
]}

Lin, Chen-Yen ^{[5
]}

Mou, Jiani ^{[5
]}

Moriarty, Susan ^{[5
]}

Lee, Chin ^{[5
]}

Gladman, Dafna ^{[6
]}

机构：

[1] Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Sch Med, Seattle, WA USA

[3] St Lukes Int Hosp, Tokyo, Japan

[4] St Lukes Int Hosp, Tokyo, Japan

[5] Eli Lilly & Co, Indianapolis, IN 46285 USA

[6] Univ Toronto, Toronto, ON, Canada

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

176

引用

页码：925 / 925

页数：1